- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cambridge Biotech Harbinger Health Raises $100M to Launch 12-Cancer Blood Tests
The funding will support commercial-scale operations and regulatory work ahead of initial rollout of Harbinger's multi-cancer early detection platform.
Apr. 14, 2026 at 12:06pm
Got story updates? Submit your updates here. ›
A translucent X-ray image reveals the intricate inner workings of Harbinger Health's cancer screening technology, hinting at the scientific advancements powering its ambitious multi-cancer detection platform.Cambridge TodayHarbinger Health, a Cambridge-based biotech company, has secured $100 million in new financing as it prepares to commercialize its HarbingerHx blood tests designed to screen for approximately 12 different cancer types. The funding will support Harbinger's efforts to move its platform from clinical trials into real-world use, including expanding laboratory operations and regulatory filings.
Why it matters
The development of multi-cancer early detection (MCED) tests like Harbinger's HarbingerHx platform represents a major scientific advancement, with the potential to significantly improve cancer outcomes through earlier diagnosis. However, experts note that practical challenges remain around follow-up care, cost, and regulatory approval that will need to be addressed as these tests move towards commercialization.
The details
Harbinger Health, a biotech company spun out of Flagship Pioneering, has raised $100 million in new financing to support the commercial launch of its HarbingerHx platform. The HarbingerHx tests use a combination of methylation-based cell-free DNA analysis and machine learning to screen for approximately 12 different cancer types. The funding will allow Harbinger to scale up its laboratory operations and complete regulatory filings as it prepares for an initial rollout of the tests. The company has also undergone a leadership transition, with Ajit Singh, who has served on Harbinger's board since 2024, being named CEO in August 2025 to oversee the shift from development to commercialization.
- Harbinger Health raised $140 million in 2023 to complete a 10,000-participant clinical study and prepare a laboratory-developed test.
- Ajit Singh was named CEO of Harbinger Health in August 2025.
The players
Harbinger Health
A Cambridge-based biotech company that has developed the HarbingerHx platform, a blood-based test designed to screen for approximately 12 different cancer types.
Ajit Singh
The CEO-Partner of Harbinger Health, who was named CEO in August 2025 as the company shifted from development to commercialization.
Flagship Pioneering
The venture capital firm that spun out Harbinger Health and lists Ajit Singh as Harbinger's CEO-Partner.
What’s next
Harbinger plans to accelerate commercial-scale lab work and regulatory filings with the new $100 million in funding, and the next big milestones are expected to include formal FDA submissions and additional clinical readouts.
The takeaway
The development of Harbinger's multi-cancer early detection platform represents a significant scientific advancement, but the company will need to navigate practical challenges around follow-up care, cost, and regulatory approval as it works to bring the tests to market. The success of Harbinger's efforts could have broader implications for Cambridge's transition from a research hub to a commercial testing center.
